You can now read 10 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

The Boston Globe

Business

Mass. Movers

Aegerion wins approval for its first drug

Aegerion can begin marketing its first drug.

istockphoto.com

Aegerion can begin marketing its first drug.

The Food and Drug Administration has approved Aegerion Pharmaceuticals’ request to market its first drug, a treatment for a rare inherited genetic disorder that can raise cholesterol to life-threatening levels. The condition is resistant to statins and other medications typically used to bring high cholesterol under control. The Cambridge biotech’s drug, Juxtapid, does carry a risk of liver toxicity, so it will come with a “black box” label — the FDA’s most serious warning level.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week